Alimta Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

Million

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Alimta Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Alimta Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Global$ 1898.7 Million$ 2328.5 Million$ 3502.1 Million5.234%
North America$ 755.68 Million$ 924.58 Million$ 1358 Million4.923%
United States$ 593.36 Million$ 725.07 Million$ 1046.64 Million4.695%
Canada$ 92.19 Million$ 111.89 Million$ 178.74 Million6.03%
Mexico$ 70.13 Million$ 87.61 Million$ 132.62 Million5.319%
Europe$ 548.72 Million$ 671.47 Million$ 993.43 Million5.018%
United Kingdom$ 68.15 Million$ 82.8 Million$ 114.55 Million4.141%
France$ 71.83 Million$ 88.29 Million$ 138.57 Million5.796%
Germany$ 84.28 Million$ 102.61 Million$ 144.85 Million4.404%
Italy$ 40.17 Million$ 49.41 Million$ 75.39 Million5.423%
Russia$ 63.98 Million$ 78.01 Million$ 109.75 Million4.36%
Spain$ 42.31 Million$ 51.49 Million$ 70.51 Million4.009%
Sweden$ 16.74 Million$ 20.27 Million$ 26.21 Million3.266%
Denmark$ 12.79 Million$ 15.36 Million$ 18.45 Million2.319%
Switzerland$ 10.92 Million$ 13.07 Million$ 17.06 Million3.381%
Luxembourg$ 7.24 Million$ 8.58 Million$ 11.4 Million3.618%
Rest of Europe$ 130.32 Million$ 161.59 Million$ 266.69 Million6.463%
Asia Pacific$ 355.05 Million$ 437.6 Million$ 704.72 Million6.137%
China$ 104.21 Million$ 128.04 Million$ 199.37 Million5.691%
Japan$ 71.93 Million$ 88.35 Million$ 137.56 Million5.691%
South Korea$ 25.49 Million$ 31.03 Million$ 45.31 Million4.849%
India$ 50.49 Million$ 62.8 Million$ 107.19 Million6.912%
Australia$ 10.55 Million$ 12.6 Million$ 17.05 Million3.853%
Singapore$ 12.75 Million$ 16.1 Million$ 27.06 Million6.703%
Taiwan$ 6.36 Million$ 7.48 Million$ 10.92 Million4.842%
South East Asia$ 33.41 Million$ 41.48 Million$ 68.64 Million6.497%
Rest of APAC$ 39.87 Million$ 49.71 Million$ 91.61 Million7.942%
South America$ 125.31 Million$ 155.59 Million$ 248.72 Million6.039%
Brazil$ 39.82 Million$ 49.37 Million$ 76.81 Million5.68%
Argentina$ 16.38 Million$ 20.4 Million$ 33.97 Million6.585%
Colombia$ 10.87 Million$ 13.45 Million$ 20.62 Million5.492%
Peru$ 5.2 Million$ 6.42 Million$ 9.62 Million5.18%
Chile$ 3.37 Million$ 4.16 Million$ 6.26 Million5.225%
Rest of South America$ 49.67 Million$ 61.79 Million$ 101.44 Million6.392%
Middle East$ 70.25 Million$ 84.69 Million$ 117.92 Million4.224%
Saudi Arabia$ 27.47 Million$ 32.97 Million$ 44.97 Million3.957%
Turkey$ 9.28 Million$ 11.09 Million$ 14.87 Million3.729%
UAE$ 7.55 Million$ 9.21 Million$ 13.87 Million5.255%
Egypt$ 6.31 Million$ 7.68 Million$ 11.16 Million4.774%
Qatar$ 5.7 Million$ 6.76 Million$ 9.07 Million3.743%
Rest of Middle East$ 13.95 Million$ 16.98 Million$ 23.98 Million4.411%
Africa$ 43.67 Million$ 54.58 Million$ 79.29 Million4.778%
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africa$ 14.48 Million$ 18.04 Million$ 25.53 Million4.434%

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.

100mg Alimta Market Analysis
XX
100mg Market Size 2025
XX %
CAGR
Locked · Full data in paid report
500mg Alimta Market Analysis
XX
500mg Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

The pharmaceutical and healthcare industry is highly competitive, with players expanding through product launches, M&A, partnerships, and regulatory approvals. The Alimta Market Analysis market report covers financials, market share, SWOTs, and responses to Tariffs, while providing global, regional, and country-level forecasts supported by value chain, patent analysis, and a competitive matrix serving as a key resource for stakeholders and investors.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Eli Lilly••• ••• ••• •••
Abbott Healthcare••• ••• ••• •••
Cadila Healthcare••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

The global Alimta (pemetrexed) market is projected for steady growth, driven by its established efficacy in treating non-small cell lung cancer (NSCLC) and mesothelioma. Despite facing significant headwinds from patent expirations and the subsequent influx of generic competitors, the market is sustained by the rising global incidence of cancer, particularly lung cancer. North America continues to hold the largest market share, attributed to high healthcare expenditure and established treatment protocols. However, the Asia Pacific region is expected to exhibit the fastest growth, fueled by improving healthcare infrastructure, rising awareness, and an increasing patient pool. The market's future trajectory will be shaped by life cycle management strategies, expansion into emerging economies, and its role in combination therapies alongside newer oncological treatments. Strategic pricing and differentiation will be crucial for brand sustainability against generic erosion.

Key strategic insights from our comprehensive analysis reveal:

  • The primary challenge for the brand is the patent cliff, leading to significant market share erosion due to the availability of lower-cost generic pemetrexed. Manufacturers must focus on value-added formulations or combination therapy research to maintain relevance.
  • Emerging markets, particularly in the Asia Pacific and South America, represent the most significant growth opportunities due to rising cancer prevalence, increasing healthcare spending, and improving access to advanced therapies.
  • The increasing adoption of Alimta as a maintenance therapy and its use in combination with other chemotherapy agents and immunotherapies will be critical for sustaining revenue streams and defending against the competition from novel targeted drugs.

Strategic Recommendations for Manufacturers

  • Implement robust life cycle management strategies, including exploring new formulations or delivery methods to offer differentiation from generics.
  • Aggressively pursue geographic expansion in high-growth emerging markets across Asia Pacific and Latin America, where generic penetration may be slower and cancer incidence is rising.
  • Invest in clinical trials to establish Alimta's efficacy in new combination regimens with next-generation immunotherapies and targeted agents, securing its role in evolving treatment paradigms.
  • Develop competitive pricing and market access strategies to effectively compete with generic alternatives, focusing on value-based arguments and securing favorable formulary placements.

The pharmaceutical and healthcare industry is growing rapidly, driven by aging populations, chronic disease prevalence, and rising healthcare spending. Innovations in precision medicine, gene therapy, and digital health are improving outcomes, though challenges include high R&D costs, strict regulations, and pricing pressures. Growth opportunities lie in emerging markets with expanding healthcare infrastructure, while key trends such as AI-driven personalized medicine, telehealth, and sustainable pharma solutions are reshaping the industry.

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Alimta Market Analysis is witnessing significant growth in the near future.

In 2023, the 100mg segment accounted for a notable share of the Alimta Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Alimta Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Eli Lilly, Abbott Healthcare, Cadila Healthcare and others are profiled in the report.
Segments include Type, Application and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Alimta Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Type100mg, 500mg
ApplicationPleural Mesothelioma, Non-small Cell Lung Cancer
List of CompetitorsEli Lilly, Abbott Healthcare, Cadila Healthcare

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Alimta Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Eli Lilly
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Abbott Healthcare
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Cadila Healthcare
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis

  • Chapter 2. Global Alimta Market Analysis

    • 2.1 Global Alimta Market Analysis
    • 2.2 Global Alimta Market Analysis by Region
    • 2.3 Global Alimta Market Analysis by Type
    • 2.4 Global Alimta Market Analysis by Application
    • 2.5 Global Alimta Market Analysis by Key Players

  • Chapter 3. North America Alimta Market Analysis

    • 3.1 North America Alimta Market Analysis
    • 3.2 North America Alimta Market Analysis by Country
    • 3.3 North America Alimta Market Analysis by Type
    • 3.4 North America Alimta Market Analysis by Application
    • 3.5 North America Alimta Market Analysis by Key Players

  • Chapter 4. Europe Alimta Market Analysis

    • 4.1 Europe Alimta Market Analysis
    • 4.2 Europe Alimta Market Analysis by Country
    • 4.3 Europe Alimta Market Analysis by Type
    • 4.4 Europe Alimta Market Analysis by Application
    • 4.5 Europe Alimta Market Analysis by Key Players

  • Chapter 5. Asia Pacific Alimta Market Analysis

    • 5.1 Asia Pacific Alimta Market Analysis
    • 5.2 Asia Pacific Alimta Market Analysis by Country
    • 5.3 Asia Pacific Alimta Market Analysis by Type
    • 5.4 Asia Pacific Alimta Market Analysis by Application
    • 5.5 Asia Pacific Alimta Market Analysis by Key Players

  • Chapter 6. South America Alimta Market Analysis

    • 6.1 South America Alimta Market Analysis
    • 6.2 South America Alimta Market Analysis by Country
    • 6.3 South America Alimta Market Analysis by Type
    • 6.4 South America Alimta Market Analysis by Application
    • 6.5 South America Alimta Market Analysis by Key Players

  • Chapter 7. Middle East Alimta Market Analysis

    • 7.1 Middle East Alimta Market Analysis
    • 7.2 Middle East Alimta Market Analysis by Country
    • 7.3 Middle East Alimta Market Analysis by Type
    • 7.4 Middle East Alimta Market Analysis by Application
    • 7.5 Middle East Alimta Market Analysis by Key Players

  • Chapter 8. Africa Alimta Market Analysis

    • 8.1 Africa Alimta Market Analysis
    • 8.2 Africa Alimta Market Analysis by Country
    • 8.3 Africa Alimta Market Analysis by Type
    • 8.4 Africa Alimta Market Analysis by Application
    • 8.5 Africa Alimta Market Analysis by Key Players

  • Chapter 9. Type Analysis

    • 9.1 100mg
      • 9.1.1 Global 100mg Market
      • 9.1.2 Global 100mg Market by Region
    • 9.2 500mg
      • 9.2.1 Global 500mg Market
      • 9.2.2 Global 500mg Market by Region

  • Chapter 10. Application Analysis

    • 10.1 Pleural Mesothelioma
      • 10.1.1 Global Pleural Mesothelioma Market
      • 10.1.2 Global Pleural Mesothelioma Market by Region
    • 10.2 Non-small Cell Lung Cancer
      • 10.2.1 Global Non-small Cell Lung Cancer Market
      • 10.2.2 Global Non-small Cell Lung Cancer Market by Region

  • Chapter 11. Qualitative Analysis (Subject to Data Availability)

    • 11.1 Market Drivers
    • 11.2 Market Restraints
    • 11.3 Market Trends
    • 11.4 Market Opportunity
    • 11.5 Technological Road Map (Subject to Data Availability)
    • 11.6 Product Life Cycle (Subject to Data Availability)
    • 11.7 Customer and Buyer Behavior Analysis
      • 11.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 11.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 11.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 11.7.4 Pricing, Affordability & Value Perception Analysis
      • 11.7.5 Customer Segmentation & Demand Pattern Analysis
    • 11.8 PESTEL Analysis
      • 11.8.1 Political Factors
      • 11.8.2 Economic Factors
      • 11.8.3 Social Factors
      • 11.8.4 Technological Factors
      • 11.8.5 Legal Factors
      • 11.8.6 Environmental Factors
    • 11.9 Industrial Chain Analysis (Subject to Data Availability)
      • 11.9.1 Industry Chain Analysis
      • 11.9.2 Manufacturing Cost Analysis
      • 11.9.3 Supply Side Analysis
        • 11.9.3.1 Raw Material Analysis
        • 11.9.3.2 Raw Material Procurement Analysis
        • 11.9.3.3 Raw Material Price Trend Analysis
    • 11.10 Porter’s Five Forces Analysis
      • 11.10.1 Bargaining Power of Suppliers
      • 11.10.2 Bargaining Power of Buyers
      • 11.10.3 Threat of New Entrants
      • 11.10.4 Threat of Substitutes
      • 11.10.5 Degree of Competition
    • 11.11 Patent Analysis (Subject to Data Availability)
    • 11.12 ESG Analysis
    • 11.13 Geopolitical Outlook
      • 11.13.1 Global Power Realignment & Strategic Alliances
      • 11.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 11.13.3 International Trade Relations & Market Access Environment
      • 11.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 11.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 11.13.6 Technology Sovereignty & Digital Geopolitics
      • 11.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 11.14 AI & Market Transformation
      • 11.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 11.14.2 AI-Driven Transformation of Industry Value Chain
      • 11.14.3 Evolution of Business Models & Revenue Streams
      • 11.14.4 AI-Driven Product, Service & Innovation Transformation
      • 11.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 12. TOP 10 Country Analysis

    • 12.1 Country 1
    • 12.2 Country 2
    • 12.3 Country 3
    • 12.4 Country 4
    • 12.5 Country 5
    • 12.6 Country 6
    • 12.7 Country 7
    • 12.8 Country 8
    • 12.9 Country 9
    • 12.10 Country 10

  • Chapter 13. Research Findings

    • 13.1 Key Takeaways
    • 13.2 Analyst Point of View
    • 13.3 Assumptions and Acronyms

  • Chapter 14. Research Methodology and Sources

    • 14.1 Primary Data Collection
      • 14.1.1 Steps for Primary Data Collection
        • 14.1.1.1 Identification of KOL
      • 14.1.2 Backward Integration
      • 14.1.3 Forward Integration
      • 14.1.4 How Primary Research Help Us
      • 14.1.5 Modes of Primary Research
    • 14.2 Secondary Research
      • 14.2.1 How Secondary Research Help Us
      • 14.2.2 Sources of Secondary Research
    • 14.3 Data Validation
      • 14.3.1 Data Triangulation
    • 14.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Alimta Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 3+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Alimta Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the alimta market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.